FDA Is Turning Its Attention to Generative AI, Digital Health Companies Should Too
FDA's August discussion paper on generative AI-enabled medical devices, its updated AI device list, and a new Deputy Commissioner for Technology and AI signal that AI policy is becoming central to the agency's strategy — and digital health companies have until October 19 to weigh in.